254 related articles for article (PubMed ID: 8063403)
21. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
Maitta RW; Datta K; Pirofski LA
Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
[TBL] [Abstract][Full Text] [Related]
22. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
Nakouzi A; Zhang T; Oscarson S; Casadevall A
Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
[TBL] [Abstract][Full Text] [Related]
23. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
[TBL] [Abstract][Full Text] [Related]
24. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
25. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
26. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
27. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
28. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
29. Complete amino acid sequence of heavy chain variable regions derived from two monoclonal anti-p-azophenylarsonate antibodies of BALB/c mice expressing the major cross-reactive idiotype of the A/J strain.
Meek K; Jeske D; Slaoui M; Leo O; Urbain J; Capra JD
J Exp Med; 1984 Oct; 160(4):1070-86. PubMed ID: 6207261
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
31. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
32. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.
Dromer F; Salamero J; Contrepois A; Carbon C; Yeni P
Infect Immun; 1987 Mar; 55(3):742-8. PubMed ID: 3546139
[TBL] [Abstract][Full Text] [Related]
33. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis.
Fleuridor R; Zhong Z; Pirofski L
J Infect Dis; 1998 Oct; 178(4):1213-6. PubMed ID: 9806064
[TBL] [Abstract][Full Text] [Related]
34. Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans.
Otteson EW; Welch WH; Kozel TR
J Biol Chem; 1994 Jan; 269(3):1858-64. PubMed ID: 8294434
[TBL] [Abstract][Full Text] [Related]
35. Complete heavy and light chain variable region sequence of anti-arsonate monoclonal antibodies from BALB/c and A/J mice sharing the 36-60 idiotype are highly homologous.
Juszczak E; Near RI; Gefter ML; Margolies MN
J Immunol; 1984 Nov; 133(5):2603-9. PubMed ID: 6207237
[TBL] [Abstract][Full Text] [Related]
36. Sequences of the VH and VL regions of murine monoclonal antibodies against 3-fucosyllactosamine.
Kimura H; Cook R; Meek K; Umeda M; Ball E; Capra JD; Marcus DM
J Immunol; 1988 Feb; 140(4):1212-7. PubMed ID: 2893825
[TBL] [Abstract][Full Text] [Related]
37. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
38. Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1.
Azmi FH; Lucas AH; Raff HV; Granoff DM
Infect Immun; 1994 May; 62(5):1776-86. PubMed ID: 8168940
[TBL] [Abstract][Full Text] [Related]
39. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
